AC Immune Company Insiders
ACIU Stock | USD 3.41 0.03 0.89% |
AC Immune employs about 133 people. The company is managed by 17 executives with a total tenure of roughly 30 years, averaging almost 1.0 years of service per executive, having 7.82 employees per reported executive. Breaking down AC Immune's management performance can provide insight into the firm performance.
Andrea Pfeifer CEO CEO CoFounder |
ACIU |
AC Immune's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AC Immune's future performance. Based on our forecasts, it is anticipated that ACIU will maintain a workforce of slightly above 130 employees by December 2024.AC Immune Management Team Effectiveness
The company has return on total asset (ROA) of (0.1204) % which means that it has lost $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3116) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. Liabilities And Stockholders Equity is likely to gain to about 193.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.8 M in 2024.Common Stock Shares Outstanding is likely to drop to about 73.3 M in 2024. Net Loss is likely to gain to about (60.5 M) in 2024
AC Immune Workforce Comparison
AC Immune is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 587. AC Immune totals roughly 133 in number of employees claiming about 23% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29. AC Immune Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. AC Immune Price Series Summation is a cross summation of AC Immune price series and its benchmark/peer.
AC Immune Notable Stakeholders
An AC Immune stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AC Immune often face trade-offs trying to please all of them. AC Immune's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AC Immune's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Andrea Pfeifer | CEO CoFounder | Profile | |
Julian Snow | VP Development | Profile | |
Nuno MD | Chief Officer | Profile | |
Christopher Roberts | Interim Fin | Profile | |
Sonia Poli | Head Science | Profile | |
Piergiorgio Donati | Chief Officer | Profile | |
Pr MD | Chief Officer | Profile | |
Joshua Drumm | Head Relations | Profile | |
JeanFabien Monin | Chief Administrative Officer | Profile | |
Howard Donovan | Chief Officer | Profile | |
Alexandre Caratsch | General Counsel | Profile | |
Gary Waanders | Senior Communications | Profile | |
Marie KoscoVilbois | Chief Officer | Profile | |
Judith Moore | Global Communications | Profile | |
Madiha Derouazi | Chief Officer | Profile | |
Joseph Wettstein | Head Officer | Profile | |
David Hickman | Head SME | Profile |
About AC Immune Management Performance
The success or failure of an entity such as AC Immune often depends on how effective the management is. AC Immune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ACIU management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ACIU management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.41) | (0.43) | |
Return On Capital Employed | (0.32) | (0.33) | |
Return On Assets | (0.30) | (0.31) | |
Return On Equity | (0.34) | (0.35) |
Please note, the imprecision that can be found in AC Immune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AC Immune. Check AC Immune's Beneish M Score to see the likelihood of AC Immune's management manipulating its earnings.
AC Immune Workforce Analysis
Traditionally, organizations such as AC Immune use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AC Immune within its industry.AC Immune Manpower Efficiency
Return on AC Immune Manpower
Revenue Per Employee | 111.3K | |
Revenue Per Executive | 870.6K | |
Net Loss Per Employee | 407.8K | |
Net Loss Per Executive | 3.2M | |
Working Capital Per Employee | 838.9K | |
Working Capital Per Executive | 6.6M |
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.